Her2 Positive Breast Cancer Clinical Trials 2024

Her2 Positive Breast Cancer Clinical Trials 2024

Her2 Positive Breast Cancer research studies recruiting patients in 2024 need your help. Receive premium care & cutting edge treatments by enrolling in her2 positive breast cancer clinical trials today.

Her Positive Breast Cancer Clinical Trials 2024

Here are the 6 most popular medical studies for her2 positive breast cancer

Popular filter options for her2 positive breast cancer trials

Breast Cancer Clinical Trials

View 74 Breast Cancer medical studies.

LABC Clinical Trials

View 74 LABC medical studies.

ER Positive Clinical Trials

View 23 ER positive medical studies.

PR Positive Clinical Trials

View 16 PR positive medical studies.

Phase 3 Her2 Positive Breast Cancer Clinical Trials

View 74 phase 3 her2 positive breast cancer medical studies.

Her2 Positive Breast Cancer Clinical Trials With No Placebo

View 74 her2 positive breast cancer medical studies that do not have a placebo group.

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to her2 positive breast cancer

What are the top hospitals conducting her2 positive breast cancer research?

Cutting-edge research and clinical trials are crucial in the quest to conquer her2 positive breast cancer, a subtype known for its aggressive nature. In Boston, Dana-Farber Cancer Institute leads the charge with nine active trials dedicated specifically to her2 positive breast cancer. These trials build upon an impressive history of 218 completed studies since their first recorded trial back in 1998. Not far behind, Memorial Sloan Kettering Cancer Center in New york has seven ongoing trials and an astounding 219 all-time her2 positive breast cancer studies under their belt. Their pioneering efforts date back to 1994, firmly establishing them as a key player in this field.

The Mayo Clinic in Rochester also contributes significantly to understanding and treating her2 positive breast cancer, currently conducting six active clinical trials focused on this specific subtype. With a legacy of 117 previously conducted studies dating back to their first recorded trial in 1998, they continue to make strides towards advancements against this challenging form of breast cancer. In sunny Fort Myers, Florida Cancer Specialists is making noteworthy progress as well with six active clinical trials targeting her2 positive breast cancer. While they have conducted fewer all-time trials than some other institutions (36 total), their dedication since recording their first trial in 1995 cannot be underestimated.

Finally, Florida Cancer Specialists' Saint Petersburg location may be relatively new compared to others on this list but it is equally committed with six ongoing clinical trials solely devoted to combating her2 positive breast cancer; having started at2013-with fifteen previous attempts they are paving the way for future breakthroughs within this evolving field.

These hospitals across different locations signify the collaborative effort required for significant medical advancements aimed at improving outcomes for individuals battling her2 positive breast cancer worldwide

Which are the best cities for her2 positive breast cancer clinical trials?

When it comes to her2 positive breast cancer clinical trials, several cities emerge as frontrunners in research and development. Boston, Massachusetts leads the pack with 37 active trials focusing on treatments like Enzalutamide, Trastuzumab emtansine (T-DM1), and PF-07220060. Nashville, Tennessee closely follows with 35 ongoing studies investigating similar interventions including Enzalutamide and Trastuzumab. Houston, Texas also demonstrates a commitment to advancing care for her2 positive breast cancer patients through their 31 active trials exploring Abemaciclib and Trastuzumab emtansine (T-DM1). New york City rounds out the list of top locations with 31 current studies investigating various treatments such as Imlunestrant and Abemaciclib. Finally, Denver, Colorado showcases its dedication to research by conducting 30 active trials examining innovative approaches like Entinostat and Therapeutic Conventional Surgery. These cities provide valuable opportunities for individuals battling her2 positive breast cancer to participate in cutting-edge clinical trials that may shape the future of treatment options.

Which are the top treatments for her2 positive breast cancer being explored in clinical trials?

The search for effective treatments for HER2 positive breast cancer is a dynamic and evolving field. Promising options currently being explored in clinical trials include:

  • Abemaciclib, which is involved in 4 active trials and has been part of 65 all-time her2 positive breast cancer trials since its introduction in 2014.
  • Trastuzumab, a well-established treatment with 4 ongoing trials and an impressive track record of 325 all-time her2 positive breast cancer trials since its initiation in 2000.
  • Olaparib, another contender making strides with involvement in three active trials and having contributed to the findings of 50 all-time her2 positive breast cancer studies since it was listed as a potential option in 2010.

These innovative treatments hold promise for improving outcomes and quality of life for patients battling this aggressive form of breast cancer.

What are the most recent clinical trials for her2 positive breast cancer?

Recent clinical trials offer promising advancements in the treatment of HER2 positive breast cancer. Phase 2 studies have explored an initial regimen designed to improve outcomes for patients with this subtype of breast cancer. Additionally, a Phase 1 trial investigated the efficacy and safety of injections containing a high dose of viral particles as potential therapy for HER2 positive breast cancer. In Phase 3 trials, two different drugs—imlunestrant and elacestrant—were evaluated for their effectiveness against HER2 positive breast cancer. Moreover, denosumab was studied in a large-scale Phase 3 trial to assess its impact on this specific type of breast cancer. These recent clinical trials provide hope for improved treatment options and outcomes among those affected by HER2 positive breast cancer.

What her2 positive breast cancer clinical trials were recently completed?

Several clinical trials for HER2-positive breast cancer have recently concluded, showcasing the ongoing progress in finding effective treatments. In November 2021, G1 Therapeutics completed a trial investigating Trilaciclib's potential in combating this type of cancer. Concurrently, HiberCell wrapped up a trial exploring Pembrolizumab as a treatment option. Other noteworthy trials include Probiotic, sponsored by Mayo Clinic and completed in July 2021; Buzzy(R), sponsored by University of Wisconsin, Madison and finished in April 2021; LY3484356 from Eli Lilly and Company, also concluded in April 2021. These studies represent important strides forward in understanding and addressing HER2-positive breast cancer to ultimately improve patient outcomes.